TRDA

Entrada Therapeutics, Inc. [TRDA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TRDA Stock Summary

Top TRDA Correlated Resources

TRDA

Top 10 Correlated ETFs

TRDA

Top 10 Correlated Stocks

TRDA

In the News

TRDA Financial details

Company Rating
-
Market Cap
435.13M
Income
-6.69M
Revenue
129.01M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
159
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-29.25
Forward P/E
-
PEG
3.16
P/S
6.51
P/B
2.29
P/C
-
P/FCF
5.21
Quick Ratio
2.14
Current Ratio
2.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.21
EPS next Y
-
EPS next Q
-
EPS this Y
-92.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-4.31%
EPS Q/Q
-127.1%
-
-
-
-
SMA20
-26.19%
SMA50
-40.81%
SMA100
-57.24%
Inst Own
-
Inst Trans
-
ROA
-4%
ROE
-9%
ROC
-0.08%
Gross Margin
100%
Oper. Margin
-30%
Profit Margin
-22%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.62-18.44
52W High
-55.83%
52W Low
-20.5%
RSI
34.17
Rel Volume
3.59
Avg Volume
76.93K
Volume
276.21K
Perf Week
-3.87%
Perf Month
-26.18%
Perf Quarter
-52.79%
Perf Half Y
-54.1%
-
-
-
-
Beta
-0.497
-
-
Volatility
0.09%, 1.25%
Prev Close
-2.21%
Price
7.95
Change
1.53%

Something similar

Top by Market Cap
AMZ.DE
0YXG.L
DHR-PB
VOO
1YD.DE
Top Correlated ETFs
HMMJ.TO
LABU
BBC
CNCR
GNOM
Top Correlated Stocks
BW
CABA
XRX
BB
CRIS
Similar Market Cap
TREE
CCLP
IHRT
TREG.L
EAGG.PA

Company Profile

Healthcare Biotechnology
  • Volume Average 76.93K
  • Market Capitalization 435.13M
  • Employee 159
  • CEO Mr. Dipal Doshi
  • Headquarters Boston,MA,US
  • IPO Date 2021-10-29
  • Website https://www.entradatx.com

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.